oricar-017
oricell therapeutics
['multiple myeloma', 'oricar-017', 'car-t']
oricar-017, an autologous gprc5d-directed car-t cell therapy in development to treat patients with relapsed/refractory multiple myeloma (mm), displayed notable efficacy and favorable safety in results from an early-phase trial (nct05016778) #asco22 
CGTLive™ delivers quality and relevant information to healthcare professionals on cell, gene, regenerative, and engineered medicines to ultimately improve care.